The core function of the Screening Group (SCR) at IARC is to provide data on the accuracy, reproducibility, efficacy, benefits, harmful effects, and cost-effectiveness of various early detection interventions for breast, cervical, colorectal, and oral cancers, among others, in reducing deaths and improving patients’ quality of life in various settings. These data can then be used to inform and improve the rational use of health-care resources. The Group’s ultimate objective is to guide the development of public health policies for implementing screening in a variety of health-care settings, in particular in low- and middle-income countries (LMICs).
SCR conducts field studies in LMICs to evaluate various early detection methods for breast, cervical, colorectal, and oral cancer control. These initiatives also address the means by which screening services could be scaled up through local public health services. SCR develops various training resources to catalyse and augment capacity building in close collaboration with national institutions and government health services. Through its research programme, SCR generates scientific evidence to support the development of resource-appropriate early detection policies and health systems for the delivery of effective early services. For example, the Group significantly contributed to the evaluation of the safety and efficacy of less than three doses of the HPV vaccine in protecting against cervical cancer.
Conference: The Federation of Obstetric & Gynecological Societies of India, wellness of woman, New Delhi, India15/02/2019 - 17/02/2019
Dr Partha Basu was the chairperson at the National conference and Training of Trainers programme on National conference of wellness of woman, “Ek Kadam Cancer se Bachao Ki Ore” and delivered presentations about NCDs and Cancer Screening, and management of VIA screened positive participants. Dr Sankaranarayanan presented the Road map for Cervical Cancer Elimination in INDIA and WHO perspective.
Visit of Dr Arn Migowski Rocha dos Santos, Chief of the Cancer Early Detection Division, National Cancer Institute (INCA), Rio de Janeiro, Brazil12/02/2019 – 15/02/2019
Dr Migowski visited the Screening Group to discuss areas of potential collaboration.
Assessment visit to Saudi Arabia12/02/2019 – 14/02/2019
Dr Partha Basu visited Saudi Arabia to evaluate the new cancer screening model included in the basic benefits package at primary health centre level implemented by the ministry of health.
|Randall T.C., Sauvaget C., Muwonge R., Trimble E.L., Jeronimo J. Authors response to Papoutsis and colleagues letter to the editor regarding: Worthy of further consideration: An updated meta-analysis to address the feasibility, acceptability, safety and efficacy of thermal ablation in the treatment of cervical cancer precursor lesions. Prev Med. 2019 Feb 10.|
|Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years - updated evidence from Indian follow up cohort study. Basu P., Muwonge R., Bhatla N., Nene B.M., Joshi S., Esmy P.O., Poli U.R.R., Joshi G., Verma Y., Zomawia E., Shastri S.S., Pimple S., Anantharaman D., Prabhu P.R., Hingmire S., Sauvaget C., Lucas E., Pawlita M., Gheit T., Jayant K., Malvi S.G., Siddiqi M., Michel A., Butt J., Sankaran S., Rameshwari Ammal Kannan T.P., Varghese R., Divate U., Willhauck-Fleckenstein M., Waterboer T., Muller M., Sehr P., Vashist S., Mishra G., Jadhav R., Thorat R., Tommasino M., Pillai M.R., Sankaranarayanan R.; Indian HPV vaccine study group. Papillomavirus Res. 2019 Jan 31. pii: S2405-8521(18)30133-2.|
|DA Silva E.M., Kay A., Lobato C., Muwonge R., Zoulim F., Brites C., Parana R., Trepo C. Non-F HBV/HDV-3 co-infection is associated with severe liver disease in Western Brazilian Amazon. J Med Virol. 2019 Jan 29.|